Clopidogrel versus prasugrel: Times are changing, but not for everyone

Pharmacotherapy

Volumn 29, Issue 12, 2009, Pages 1393-1396

  Dobesh, Paul P ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ACS; Acute coronary syndrome; Antiplatelets; Cardiology; Clopidogrel; Coronary artery disease; Prasugrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; CLINICAL EVALUATION; DRUG SAFETY; EDITORIAL; FOLLOW UP; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RISK REDUCTION; STROKE;

ACUTE CORONARY SYNDROME; CLINICAL TRIALS AS TOPIC; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 73349090577     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.12.1393     Document Type: Editorial

References (16)

1. . Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics - 2008 update. A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation 2008;117:e25-146.
2. . Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non - ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 2002 guidelines for the management of patients with unstable angina/non - ST-elevation myocardial infarction). J Am Coll Cardiol 2007;50:e1-157.
3. . Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2008;51:210-47.
4. . Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2008;51:172-209.
5. . Reinhart KM, White CM, Baker WL. Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy 2009;29:1441-51.
6. . The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Errata in N Engl J Med 2001;345:1506, 1716.)
7. . Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357: 2001-15.
8. . Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - thrombolysis in myocardial infarction 38. An application of the classification system from the universal definition of myocardial infarction. Circulation 2009;119;2758-64.
9. . Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy 2009;29:1089-102.
10. . Payne CD, Grace Y, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-62.
11. . Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-16.
12. . Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560-4.
13. . Wiviott SD, Trenk D, Frelinger Al, et al, for the PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patient with planned percutaneous coronary intervention. The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923-32.
14. . Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention. A TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - thrombolysis in myocardial infarction) analysis. J Am Coll Cardiol 2008;51:2028-33.
15. . Alexander KP, Roe MT, Chen AY, et al, for the CRUSADE Investigators. Evolution in cardiovascular care for elderly patients with non - ST-segment elevation acute coronary syndromes. Results from the CRUSADE national quality improvement initiative. J Am Coll Cardiol 2005;46:1479-87.
16. . Sabatine MS, Cannon CP, Gibson CM, et al, for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.